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Patient- and population-level health
consequences of discontinuing antiretroviral
therapy in settings with inadequate HIV
treatment availability
April D Kimmel1,2,3*, Stephen C Resch3, Xavier Anglaret5,6, Norman Daniels3, Sue J Goldie3, Christine Danel6,
Angela Y Wong7, Kenneth A Freedberg3,4,7 and Milton C Weinstein3,4

Abstract
Background: In resource-limited settings, HIV budgets are flattening or decreasing. A policy of discontinuing
antiretroviral therapy (ART) after HIV treatment failure was modeled to highlight trade-offs among competing policy
goals of optimizing individual and population health outcomes.
Methods: In settings with two available ART regimens, we assessed two strategies: (1) continue ART after
second-line failure (Status Quo) and (2) discontinue ART after second-line failure (Alternative). A computer model
simulated outcomes for a single cohort of newly detected, HIV-infected individuals. Projections were fed into a
population-level model allowing multiple cohorts to compete for ART with constraints on treatment capacity. In the
Alternative strategy, discontinuation of second-line ART occurred upon detection of antiretroviral failure, specified
by WHO guidelines. Those discontinuing failed ART experienced an increased risk of AIDS-related mortality
compared to those continuing ART.
Results: At the population level, the Alternative strategy increased the mean number initiating ART annually by
1,100 individuals (+18.7%) to 6,980 compared to the Status Quo. More individuals initiating ART under the
Alternative strategy increased total life-years by 15,000 (+2.8%) to 555,000, compared to the Status Quo. Although
more individuals received treatment under the Alternative strategy, life expectancy for those treated decreased by
0.7 years (−8.0%) to 8.1 years compared to the Status Quo. In a cohort of treated patients only, 600 more
individuals (+27.1%) died by 5 years under the Alternative strategy compared to the Status Quo. Results were
sensitive to the timing of detection of ART failure, number of ART regimens, and treatment capacity. Although we
believe the results robust in the short-term, this analysis reflects settings where HIV case detection occurs late in the
disease course and treatment capacity and the incidence of newly detected patients are stable.
Conclusions: In settings with inadequate HIV treatment availability, trade-offs emerge between maximizing
outcomes for individual patients already on treatment and ensuring access to treatment for all people who may
benefit. While individuals may derive some benefit from ART even after virologic failure, the aggregate public
health benefit is maximized by providing effective therapy to the greatest number of people. These trade-offs
should be explicit and transparent in antiretroviral policy decisions.
Keywords: HIV, AIDS, Antiretroviral therapy, ART, Discontinuation, Population health, Ethics, Limited resources
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Background
While international initiatives to combat HIV have facilitated major increases in antiretroviral therapy (ART)
availability, coverage remains limited [1]. The treatment
gap relates to inadequate HIV detection and linkage to
care [2], as well as drug stock-outs, funding constraints,
and staff and space shortages, contributing to treatment
suspensions and waiting lists [3-5]. These obstacles persist when international HIV treatment guidelines call for
earlier ART initiation and consideration of additional
antiretroviral regimens, which suggest an increasing demand for ART [6]. Changing political priorities and the
global financial crisis have also jeopardized external financial commitments to HIV treatment and care [7].
Understanding the range of different treatment alternatives, as well as their associated benefits, costs, and
uncertainty, can make trade-offs in clinical policy decisions more explicit. To understand the implications of
one area — ART after treatment failure — our objective
was to assess a policy of ART discontinuation after
failure by creating a stylized depiction of antiretroviral
therapy allocation. In so doing, we aimed to highlight
trade-offs among competing policy goals of optimizing
health outcomes for treated patients, health outcomes for
treated and untreated patients, and the number receiving
treatment when treatment availability is inadequate.
Methods
Overview

This analysis relied on a two-stage modeling approach.
We first used a computer model of HIV disease to simulate health outcomes for a cohort of newly detected,
HIV-infected individuals in the absence of treatment
constraints. We then used these estimates as inputs to a
population-level model that allocated treatment across
multiple cohorts of newly detected, HIV-infected individuals when treatment capacity was limited. Clinical data
were from clinical trials and cohort studies in Côte
d’Ivoire, West Africa [8-10]. We evaluated strategies for
discontinuing ART (discontinue or not) according to life
expectancy, averaged across multiple cohorts of detected
HIV-infected individuals. Other performance measures
included the mean number initiating treatment annually,
mean time on treatment, and mean number alive
annually. We conducted sensitivity analyses to examine
how key variables and assumptions influenced results.
Strategies

We evaluated two treatment strategies: (1) continue
ART after second-line ART failure (Status Quo), and (2)
discontinue ART after second-line ART failure (Alternative). Both strategies include treated as well as untreated,
HIV-infected individuals.
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In defining the strategies, we made several assumptions. First, all individuals receive two sequential antiretroviral regimens and treatment efficacy is fixed over
time [6]. Second, individuals receive semi-annual clinical
and immunologic monitoring to assess treatment
response, and have quarterly clinic visits [6]. Third, in
accordance with WHO guidelines and consistent with
clinical care in many resource-limited settings, immunologic and clinical criteria are used to initiate ART, diagnose ART failure, and inform decisions related to
regimen switching including, if applicable, discontinuation after second-line failure. ART failure criteria
are defined as an observed 50% decrease in peak ontreatment CD4 count, CD4 count <100 μL, CD4 count
below pre-ART nadir, or a new WHO stage III/IV
event, excluding tuberculosis and severe bacterial infections [6].
Models
Individual-level model

We used a previously described individual-level simulation model (Cost Effectiveness of Preventing AIDS Complications-International) to project strategy-specific life
expectancy, the fraction of a cohort receiving treatment
annually, and the fraction surviving each year in a single
cohort [11-14]. The model simulates a cohort of individual patients whose clinical course is tracked from model
entry until death. Disease progression is a function of
HIV RNA level, which determines the rate of CD4 count
decline and, in turn, the risk of specific opportunistic
infections and death [15]. For patients receiving ART,
virologically suppressed patients experience HIV RNA
decreases and CD4 count increases, with a decrease in
CD4-specific morbidity and mortality; a fraction of those
virologically suppressed experience no CD4 increase in
response to treatment [16]. Patients with virologic failure
but who remain on ART have an independent reduction
in AIDS-related mortality compared to those not receiving ART [17]. Patients on ART who become lost to
follow-up experience an initial period of increased risk
of morbidity and mortality compared to those not lost;
those who are lost and experience a WHO stage IV
event may re-enter care [18].
Population-level model

We used estimates from the individual-level simulation
model as inputs to a population-level linear programming model to estimate health outcomes in the total
HIV-infected population, including untreated patients,
when there are real-world constraints on treatment capacity. The population-level model seeks to maximize
accumulated life-years for multiple cohorts of newly
detected, HIV-infected individuals. The model chooses
an optimal fraction of each cohort to receive ART,
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subject to constraints on treatment capacity. The constraint on capacity is in the form of treatment slots,
defined as the number treated annually, which serves as
a proxy for the many constraints (e.g., financing, human
resource capacity, health and social service capacity, and
personnel affordability) faced by public sector ART programs. Time on ART per treated patient determines
consumption of these slots. The model is specified formally in the Additional file 1.
Analysis

We compared the relative performance of strategies
using long-term health outcomes, or life expectancy per
cohort. We also evaluated total life-years accumulated
across cohorts and, to address a competing policy objective of treating as many persons as possible, the mean
number of individuals initiating treatment annually. In
addition, we examined ART coverage, defined as the
ratio of the number receiving treatment annually to the
number qualifying for treatment annually, and strategyspecific survival over time. We evaluated each outcome
over a 5-year analytic time horizon.
Input parameters
Individual-level model

Cohort characteristics and natural history. Data were
from trials and cohort studies conducted in Côte d’Ivoire
by the Programme PAC-CI. Initial distributions of age,
sex, and CD4 count were derived from the ACONDA
cohort, an observational cohort of HIV-infected adults
and a continuation of the ANRS 1203 Cotrame cohort
study in Abidjan (Table 1) [18,19]. Incidence of opportunistic infections, HIV-related mortality, and efficacy
and toxicity of cotrimoxazole prophylaxis were from
ANRS 059 trial data, as well as from the ANRS 1203
and 1220 study cohorts [9,10,20]. Risk of nonHIV–related mortality was from country-specific life
tables for Côte d’Ivoire [21].
ART. Effectiveness of non-nucleoside reverse transcriptase inhibitor-based first-line ART was from a cohort of treatment-naïve patients in Abidjan (at 24 weeks,
80.2% of patients HIV RNA suppressed to ≤300 copies/
mL and median CD4 count increase of 152 cells/μL
(IQR 64/μL, 201/μL)) [22]. We assumed that the effectiveness of protease inhibitor- (PI-) based second-line
ART, and, in sensitivity analysis, of a third-line regimen
was similar to that of first-line ART. Five percent of
those virologically suppressed experienced a discordant
response, or no immunologic response to ART [16]. In
addition, 15% of patients receiving ART were lost to
follow-up by 18 months [18]; among those lost, we
assumed 50% of those who later experienced a WHO
stage IV event re-entered care.
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Table 1 Selected data for the individual-level model
Variable

Base case value

Reference(s)

Mean age (SD) (yrs)

36.9 (9.2)

Touré et al. [18]

Gender distribution

70% female

Touré et al. [18]

Mean CD4 count (SD)
(cells/μL)

140 (116)

Touré et al. [18]

Median HIV RNA (IQR)
(log10 copies/mL)

5.3 (4.8–5.8)

Seyler et al. [19]

HIV RNA suppression
at 24 weeks

80.2%

Messou et al. [22]

CD4 count increase
at 24 weeks (cells/μL)†

+152

Messou et al. [22]

5%

Grabar et al. [16]

18-month cumulative
loss to follow-up

15%

Touré et al. [18]

Probability of returning
to care if WHO stage IV event

50%

Assumption

Initial cohort characteristics

First- and second-line
antiretroviral efficacy*

Probability of discordant
response
Loss to follow-up

SD standard deviation, WHO World Health Organization, NNRTI non-nucleoside
reverse transcriptase inhibitor, PI protease inhibitor, IQR interquartile range.
*First-line antiretroviral therapy (ART) efficacy data were derived from the
ACONDA cohort, in which 52% received an initial ART regimen of stavudine,
lamivudine, and nevirapine; 22% received stavudine, lamivudine, and
efavirenz; and 20% received zidovudine, lamivudine, and efavirenz (with the
remaining 6% receiving other regimens). We assumed a dosing scheduled in
accordance with WHO recommendations — 300 mg once daily (zidovudine),
150 mg twice daily (lamivudine), 30 mg twice daily (stavudine), 600 mg once
daily (efavirenz), and 200 mg once daily (nevirapine). In the absence of data,
we assumed that second-line ART suppression rates were identical to that for
first-line ART.
†For first-line ART, CD4 count increases were 76 (standard deviation (SD) 19)
cells/μL per month for months 1–2 and 4 (SD 1) cells/μL per month thereafter.
We assumed similar CD4 response for second-line ART.

Population-level model

The individual-level model produced several projections
used as inputs to the population-level model. These
included: (1) strategy-specific life expectancy, and (2)
the number receiving ART annually, which was used to
derive the strategy-specific annual probability of receiving ART and cohort and strategy-specific annual treatment need.
For parameters regarding the number of newly
detected patients annually and total treatment slots, we
drew upon projections from the UNAIDS Spectrum
model and recent data on antiretroviral coverage, both
for Côte d’Ivoire. Spectrum model estimates for the
number needing first-line ART annually (30,000) were
used as a proxy for the number newly detected each
year, since most HIV-infected individuals present with
relatively advanced disease and are, therefore, eligible for
ART upon detection [23]. Estimates of the total number
of treatment slots at any one time (50,000) were based
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Table 2 Base case results: individual- and population-level antiretroviral health benefits in a setting with inadequate
treatment availability
Treated individuals only

Treated and untreated individuals†

Strategy*

Life
expectancy
(Years)

Mean time
on treatment
(Years)

Mean
number
initiating
treatment
annually

Life
expectancy
(Years)

Total
life-years
(Years)

Mean
annual
treatment
coverage{
{ (%)

Status Quo

8.8

7.4

5,880

3.6

540,000

24.4

Alternative

8.1

6.3

6,980

3.7

555,000

29.0

*In the Status Quo, antiretroviral therapy (ART) is never discontinued. In the Alternative strategy, ART is discontinued when second-line ART failure is observed. In
the base case, ART failure is defined as a 50% decrease in peak on-treatment CD4 count, CD4 count <100 cells/μL, CD4 count below pre-ART nadir, or a WHO
stage III/IV event, excluding tuberculosis and severe bacterial infections [6]. On average, individuals who received no treatment lived approximately 1.9 years.
†Results are presented for a 5-year analytic time horizon for a cohort of 30,000 newly detected HIV-infected individuals entering care annually.
{Treatment coverage is defined as the ratio of the number receiving treatment annually to the number qualifying for treatment annually.

Base case

For a cohort of newly detected HIV-infected individuals
with mean CD4 140 cells/μL and no access to ART, life expectancy was 1.9 years. For treated individuals only, compared to the Status Quo, the Alternative strategy decreased
life expectancy from 8.8 to 8.1 years (Table 2). Under the
Alternative strategy, treated individuals spent 6.3 years on
ART, or 1.1 years less than under the Status Quo.
Mean time on ART among treated individuals influenced the number initiating treatment annually when
multiple cohorts of newly detected individuals competed
for treatment slots (Table 2). Of the 150,000 identified
over 5 years, 5,880 individuals on average initiated ART
annually under the Status Quo, resulting in life expectancy
per cohort of 3.6 years; 540,000 accumulated life-years
(3.6 years x 30,000 individuals/cohort x 5 cohorts =
540,000 life-years); and ART coverage of 24.4%. Compared
to the Status Quo, the Alternative strategy increased the
mean number initiating ART annually by 1,100 to 6,980,
which increased life expectancy per cohort by 0.1 years to
3.7 years; total life-years accumulated by 15,000 to 555,000
life-years; and ART coverage by 18.9% to 29.0%.
To gain further insight into the health consequences
of each strategy, we also evaluated strategy-specific survival (Figure 1). At 5 years, 62% survived under the Status Quo compared to 59% under the Alternative
strategy. Of the 5,880 individuals initiating ART annually
under the Status Quo, 2,210 died over 5 years, compared
to 2,810 among the 6,980 individuals initiating ART
under the Alternative strategy. This resulted in 600 more
deaths over 5 years for a single cohort of treated individuals under the Alternative strategy compared to the
Status Quo. For a single cohort of treated and untreated
individuals, there were 1,120 fewer deaths under the
Alternative strategy compared to the Status Quo over a
5-year period.

We evaluated the impact of uncertain parameters and
assumptions on the results (Figure 2). Among treated
and untreated individuals, the advantage of the Alternative strategy compared to the Status Quo was most

1.0
Proportion Alive

Results

Sensitivity analysis

0.8
0.6
0.4
0.2
0.0
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on recent UNAIDS data on the total number receiving
ART in Côte d’Ivoire [24].

0.8
0.6
0.4
0.2
0.0
5
6
7
Time (years)
Status Quo
Alternative

Figure 1 Survival, by strategy, for a single cohort of treated
individuals only (Upper Panel) and a single cohort of both
treated and untreated individuals (Lower Panel) when
treatment slots are limited to 50,000. On the x-axis is time; on
the y-axis is the proportion alive. By 5 years, survival among a single
cohort of treated individuals in the Status Quo exceeds survival
among treated individuals in the Alternative strategy. In contrast, for
a single cohort of treated and untreated individuals followed over
5 years, survival under the Alternative strategy exceeds survival
under the Status Quo.
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Figure 2 Sensitivity analysis: percent difference of the Alternative strategy compared to the Status Quo for two health outcomes.
Variation in health outcomes is shown on the horizontal axis and results from changes in select individual-level model parameters, which are
listed on the vertical axis. To the left of the origin (i.e., 0%) is the percent difference of the Alternative strategy compared to the Status Quo
regarding mean time on treatment among treated individuals (dark purple) and life expectancy of treated individuals (light purple). To the right
of the origin is the percent difference of the Alternative strategy compared to the Status Quo regarding the mean number initiating antiretroviral
therapy (ART) annually (dark green) and life expectancy of both treated and untreated individuals (light green). “+HIV RNA monitoring” refers to
the addition of both HIV RNA monitoring to base case assumptions. “" Discordant response” indicates an increase in the fraction of discordant
responses to ART (i.e., no immunologic response to ART among those virologically suppressed) from 5% to 19.1%. “ART effect” refers to the
independent effect of ART on AIDS-related mortality. The percent difference in life expectancy among treated and untreated individuals for the
Alternative strategy compared to the Status Quo is less than among treated individuals only, a sub-population in this analysis. Therefore, the
percent difference in life expectancy at the population level serves as a conservative estimate of the public health benefit of the Alternative
strategy. ART: antiretroviral therapy; LTFU: loss to follow-up; LE: life expectancy.

sensitive to: timing of detecting ART failure, the number
of available ART regimens, and the independent effect
of ART on AIDS-related mortality. The advantage of the
Alternative strategy was less sensitive to timing of ART
initiation (e.g., later ART initiation at CD4 <200 cells/μL
as recommended in the 2006 WHO guidelines [25]),
second-line virologic suppression, probability of later
virologic failure after initial suppression, and increases in
the proportion of discordant response to ART. However,
while results were sensitive to large increases (or
decreases) in 18-month loss to follow-up as shown in
Figure 2, they were less sensitive to small variations
in this value. For example, we evaluated a scenario in
which 18-month loss to follow-up increased 10%, a value
in line with data on loss to follow-up from some higher
prevalence settings [26]. Here, among treated individuals
only, the Alternative strategy decreased life expectancy
from 8.5 to 7.8 years (−8.2%) compared to the Status
Quo. On average, treated individuals received ART for
6.0 years, or 0.9 fewer years on ART (−15.7%) compared
to the Status Quo. This increased the number of ARTeligible individuals initiating treatment by 1,130 to 7,300
(+18.3%) and increased accumulated life-years by 10,000
to 560,000 life-years (+1.9%) (see Additional file 1). In
contrast, results were less sensitive to assumptions made
about returning to care once an individual is lost from
care, including if we specified that individuals lost who

later had a WHO stage IV event did not re-enter care
(see Additional file 1).
Sensitivity analyses also suggested that the populationlevel advantage of the Alternative strategy decreased as
the number of antiretroviral regimens increased. For example, if only a single ART regimen were available, as
might occur if second-line options are severely limited
[27], treated individuals only lived 1.3 fewer years
(−17.8%) and spent 2.1 fewer years on ART (−33.9%)
under the Alternative strategy compared to the Status
Quo, resulting in 4,020 more individuals initiating ART
annually (+56.7%) and 42,000 more accumulated lifeyears at the population level (+7.9%). If as many as three
ART regimens were available, treated individuals only
lived 0.5 fewer years (−5.3%) and spent 0.6 fewer years
on ART under the Alternative strategy compared to the
Status Quo (−7.5%), resulting in 540 more individuals
initiating ART annually (+10%) and 8,000 more accumulated life-years at the population level (+1.5%) (see
Figure 2 and Additional file 1).
Assumptions about treatment capacity most influenced the health benefits for treated and untreated
individuals. For every 5,000 additional treatment slots
available, life expectancy per cohort increased approximately 2 life-months; this gain was accompanied by
increases in the number initiating ART annually,
total accumulated life-years, and ART coverage. The
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Alternative strategy maximized life expectancy per cohort and the number initiating ART annually unless
treatment capacity exceeded 175,000 slots (corresponding to antiretroviral coverage of approximately 85%) or,
alternatively, when the annual incidence of newly
detected cases was <10,000 per year. In these two
instances, the Status Quo maximized life expectancy per
cohort.
Finally, to gain insight into real-world variation in
treatment supply and demand, we relaxed the steadystate assumption of constant treatment capacity and
allowed capacity to increase over time while holding
constant the number of newly detected patients per cohort (Figure 3). At or below 4,000 additional treatment
slots annually, the Alternative strategy remained optimal.
Above this threshold, life expectancy per cohort was
maximized by the Status Quo.

Discussion
With evidence of recent funding shortfalls, continued
obstacles to treatment provision, and flattening donor
21,000
Life Expectancy
Per Cohort
Alternative
Status Quo

7.5
7.0

Mean Number Initiating
ART Annually
Status Quo
Alternative

6.5

19,000
17,000
15,000

6.0
13,000
5.5
11,000

5.0

9,000

4.5

7,000

4.0
3.5

Mean Number Initiating ART Annually

Life Expectancy Per Cohort (Years)

8.0

5,000
0

4,000
8,000
12,000
16,000
Annual Increase in Number of Treatment "Slots"

Figure 3 Sensitivity analysis: impact of increasing treatment
capacity over time. This figure illustrates the impact on two health
outcomes of increasing treatment capacity over time, while holding
the incidence of newly detected patients constant. On the
horizontal axis is the annual increase in the number of treatment
“slots”. Variation in the number of additional treatment slots annually
impacts life expectancy per cohort (left vertical axis) and the mean
number initiating antiretroviral therapy (ART) annually (right vertical
axis). Below an annual increase of approximately 4,000 treatment
slots, life expectancy per cohort under the Alternative strategy
(dashed line) exceeds life expectancy per cohort under the Status
Quo (solid line). Above this threshold, the relationship reverses and
life expectancy per cohort under the Status Quo exceeds that under
the Alternative strategy. In contrast, regardless of the annual increase
in treatment capacity, the mean number initiating ART annually
under the Alternative strategy (orange) always is greater than the
mean number initiating ART annually under the Status Quo (blue).
However, the difference in the mean number initiating ART annually
between the two strategies begins to decrease when treatment
capacity exceeds 62,000 treatment slots, or an approximate 25%
increase, at any one time.
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funding across resource-limited settings, we sought to assess the consequences and identify the trade-offs associated
with one HIV treatment policy decision — antiretroviral
discontinuation after treatment failure. To do so, we evaluated life expectancy for individual treated patients; life
expectancy for an HIV-infected population, including
treated and untreated individuals; and the number receiving treatment when discontinuing ART compared to the
current standard of care (i.e., lifelong ART).
Results confirm that among treated individuals only,
treatment discontinuation results in lower life expectancy and decreased treatment resource consumption.
Among both treated and untreated individuals, however,
discontinuing treatment among those who have failed it
increases the total number of individuals receiving therapy, and thereby increases life expectancy per cohort
among all newly detected HIV-infected individuals. This
relationship holds across a variety of different assumptions, including many levels of treatment capacity, ART
initiation criteria, number of treatment regimens, and
timing of antiretroviral failure detection.
This research highlights concerns regarding the responsibility health care providers feel to patients directly
under their care compared to those in the wider community. In this analysis, more deaths occur over the analytic time horizon for treated individuals under the
Status Quo compared to the Alternative strategy. This
finding underscores both clinical and ethical concerns in
resource-limited settings. First, some fraction of deaths
among treated individuals are deaths which would likely
be avoidable with less misclassification of ART failure
[28]. Out of concern for and responsibility to patients
under their care, many health care providers would
choose not to implement, or even consider, a treatment
discontinuation policy unless a treated patient was not
receiving any ART-related health benefits. In settings
where HIV RNA and/or genotype tests are not available,
a discontinuation policy implies ART may be withdrawn
while it is still effective, due to discordance between
immunologic and virologic failure and uncertainty
regarding the underlying cause of virologic failure (e.g.,
non-adherence). Given the lack of adequate diagnostic
surrogates for both HIV RNA and genotype tests, a discontinuation policy might only be feasible in settings
with access to these tests.
Further, the increased number of deaths under the Alternative strategy, compared to the Status Quo, are
deaths for which a health care provider would feel immediately responsible. Indeed, health care providers, as
providers, would oppose a policy of treatment discontinuation because of their sense of obligation to offer
the best treatment to patients under their care. This opposition might well continue even if another person
could potentially benefit more from the discontinued
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treatment. Therefore, even if misclassification of antiretroviral failure were eliminated, concerns about patient
abandonment and, for physicians, mindfulness of the
Hippocratic Oath may well persist even if fewer deaths
occurred in the overall HIV-infected population under
the Alternative strategy compared to the Status Quo.
For these reasons, when conflict exists between the
health outcomes of individual patients in care and those
of the larger community, it is important for clinicians
and public health authorities to work closely together, so
that policy discussions consider both the best interests
of individual patients as well as the wider population.
Increasing treatment capacity over time highlights
trade-offs associated with the goals of different treatment policies. With more modest capacity increases over
time, discontinuing treatment not only maximizes life
expectancy per cohort, but also allows more individuals
to receive treatment, improving both efficiency and
equity. With greater capacity increases over time, however, the Status Quo (i.e., not discontinuing treatment)
maximizes life expectancy per cohort, yet does not allow
more individuals to receive treatment. In this case, the
greater health benefits associated with lifelong treatment
outweigh the increased numbers of individuals who initiate, but later discontinue, ART. Therefore, efficiency
improves but at the expense of equity. This illustrates
the tension, given a specific treatment capacity, between
keeping individuals on treatment longer and treating
more people. While this model was developed to address
efficiency concerns and maximize life expectancy per cohort, instances could arise in which concerns about
equity override efficiency. This might occur, for example,
if society values certain distributions of services (i.e.,
more individuals receiving ART under a discontinuation
policy) more highly than overall population benefit
resulting from a particular treatment policy.
While obstacles exist to implementing an antiretroviral
discontinuation policy when treatment failure has occurred and treatment availability is inadequate, political
challenges may limit the broader discussion and formulation of clearly articulated prioritization policies. Indeed, the adoption of such policies can be influenced by
the prospect of far-reaching influence (e.g., a majority
vote); targeted impact (e.g., interest groups, such as
funding agencies, health authorities, or activists); political reward (e.g., media or public opinion polling, legacy,
or mandates); or individual reward (e.g., seeking policies
that will increase personal advantage at the expense
of societal benefit), all of which policy makers may consider in the policy acceptance and/or implementation
process [29-31].
While this study suggests greater public health benefits
could be realized through implementation of the Alternative strategy when treatment availability is inadequate,
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additional challenges exist regarding explicit priority setting even when resources are severely constrained. Given
the complexity of resource allocation decisions, Mechanic, while acknowledging the role of explicit rationing
decisions in providing a framework for medical care, has
cautioned against formal rationing in the doctor-patient
relationship and the process of care provision [32]. He
argues that the process of providing medical care develops both personally and iteratively, relying on patient
trust and diverse preferences rather than the implementation of rigid standards and a one-size-fits-all approach.
These personal relationships result in exceptions to the
rule in the process of providing care. However, explicit
rules or standards of care may lack flexibility in their implementation, may be subject to political manipulation,
and may lag behind the changing reality of clinical care
and uncertainty in the evidence base. In the current climate, he later argues, these challenges can begin to be
met through several mechanisms, including patient advocacy within frameworks of procedural justice and fair
process, expanded responsibility for population health,
more collaborative and participatory partnerships with
patients, and practicing of medicine that has transparent
rationales and a clear evidence base [33]. Ham and
Coulter propose an integrated approach to priority setting that they believe captures the complexity of allocation decisions in practice [34]. Recognizing that while
explicit priority setting can enhance fairness, political accountability, and transparency, they cite the need for an
improved informational and institutional base to inform
decision making. Continued quantification and articulation of priority decisions by experts complemented by
strengthened institutions that can better incorporate input from both experts and, in particular, the public are
recommended [34].
This study has several limitations. First, we assume the
number of treatment regimens available and antiretroviral regimen efficacy is fixed over time. We found, however, that the results hold with fewer as well as more
antiretroviral regimens, though the impact is mitigated if
more regimens are available. Second, similar to treatment slots, time on treatment was chosen as a proxy for
the consumption of HIV treatment resources. Third, this
analysis relied mainly on data available from Côte
d’Ivoire, which may limit the generalizability of results.
However, parameter estimates generally fall within the
confidence intervals of data from other resource-limited
settings, including first- and second-line ART effectiveness at 24 weeks and 18-month loss from care
[27,35-38]. While this allows drawing of broad policy
conclusions about antiretroviral discontinuation after
treatment failure, context-specific analyses that rely on
sound, local data should be conducted in settings where
complete treatment availability may be inadequate.
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Fourth, while the population model implicitly includes
costs in the treatment slot constraint, the analysis does
not explicitly account for ART costs, a key driver of policy decisions in this context [39]. However, it is unlikely
that policy conclusions would change were ART and opportunistic infection costs included in the analysis. This
is because the higher cost of continued second-line ART
after first-line antiretroviral failure under the Status Quo
strategy would outweigh the combined costs of: (a)
newly enrolled patients on less expensive first-line ART,
including transaction or start-up costs associated with
treatment enrollment, and (b) treatment for opportunistic infections among those discontinuing treatment
under the Alternative strategy. Therefore, at the population level, the comparative advantage of the Alternative
strategy compared to the Status Quo would remain similar or be strengthened if costs related to treatment and
care were included.
Fifth, in the population model, we assume a steady
state situation, in which there is a constant incidence of
newly detected cases, distribution of patient characteristics of detected cases, and availability of treatment. In
the short-term, as in the 5-year time horizon in this analysis, steady state assumptions may be plausible. For example, recent reports suggest that the HIV epidemic has
stabilized in some sub-Saharan African countries [40],
indicating that HIV incidence, and potentially, the incidence of newly detected patients, could remain relatively
stable in the short-term in some settings. However, prevention effects of ART, which evidence shows decrease
the risk of HIV transmission [41,42], may result in lower
numbers of newly HIV-infected individuals annually,
lower numbers of newly detected cases annually, and potentially decreased demand for HIV treatment in the
longer term. In addition, a larger fraction of treated individuals would have effective viral suppression under the
Alternative strategy, which would increase the population health advantage of the Alternative strategy compared to the Status Quo. In the current economic
climate of flat or decreasing HIV treatment budgets, it is
also reasonable to assume that capacity, in the form of
treatment slots, might remain constant over a fixed time
horizon. However, if voluntary counseling and testing
efforts and/or treatment scale-up efforts continue, it is
unlikely that treatment demand, in the form of newly
detected patients, and treatment capacity will remain
fixed over time.
Finally, in the population-level model, we assume individuals could initiate ART only upon HIV case detection.
In settings where HIV case detection occurs late in the
course of disease (typically CD4 <200 cells/μL) [43], as
in this analysis, the vast majority of individuals entering
a treatment program are already ART eligible. Thus,
precluding later treatment initiation once the eligibility

Page 8 of 10

criterion is met has little effect on the results. If individuals eligible to initiate treatment upon detection, but
for whom no treatment slot was available were able to
subsequently initiate ART, the health benefit achieved by
these individuals would likely be less than among individuals initiating ART immediately upon detection. Therefore, in this model, which maximizes life expectancy per
cohort, the remaining fraction of a previous cohort
would not be selected to receive ART if competing
with newly detected individuals who could achieve
higher life expectancy.

Conclusions
As obstacles to providing HIV treatment persist in
resource-limited settings, questions regarding resource
allocation and priority setting necessarily emerge. Assessment of antiretroviral discontinuation policies can
highlight the trade-offs associated with policy goals of
maximizing life expectancy of treated individuals only,
life expectancy of the entire population, and the number
of individuals receiving treatment. While individuals receiving ART may continue to derive some treatment
benefit even after virologic failure, the aggregate public
health benefit is maximized by providing effective therapy to the greatest number of people. Individual- and
population-level health trade-offs should be debated and
discussed, with these trade-offs made explicit and more
transparent in treatment policy decisions.
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